The splicing factor epithelial splicing regulatory protein 1 has been shown to promote endocrine resistance and confer poor prognosis to patients with ER+ breast carcinoma by affecting lipid metabolism including the expression of FASN [16]. This evidence concerns the gene FASN and breast carcinoma.